Summary. The macrolide, FK-506, is a potent and effective inhibitor of lymphocyte activation. We studied the effects of FK-506 on human neutrophil activation induced by chemoattractants and by various substances which circumvent receptor stimulation. After preincubation for 5 min at 37 °C, FK-506
Introduction
Human neutrophils play an important role in non-specific host defense against bacterial infections (Malech and Gallin 1987) . In neutrophils and differentiated HL-60 cells, receptors for platelet activating factor (PAF), complement C5a, leukotriene B 4 and N-formyl-L-methionyl-L-leucyl-L-phenylalanine (fMet-Leu-Phe), couple to heterotrimeric regulatory guanine nucleotide-binding proteins (G-proteins) (Rossi 1986; Sandborg and Smolen 1988; Dillon et al. 1988; Seifert and Schultz 1991) . Activation of G-proteins results in phosphoinositide degradation with subsequent activation of protein kinase C, increase in cytosolic Ca 2+ concentration [Ca2+] i , activation of superoxide (02) production and exocytosis (Rossi 1986; Sandborg and Smolen 1988; Dillon et al. 1988; Seifert and Schultz 1991) .
FK-506 is an immunosuppressant macrolide from Streptomyces tsukabaensis (Kino et al. 1987) . The in vivo and in vitro effects of FK-506 and cyclosporin A (CsA) are similar, although there are substantial differences in potency and chemical structure of the immunosuppressants (Sigal and Dumont 1992) . Similar to CsA, FK-506 inhibits mitogenic or antigenic stimulation of Tand B-lymphocytes at early stages (Wicker et al. 1990; Chang et al. 1991; Sigal and Dumont 1992) . In addition, FK-506 and CsA interfere with signal transduction pathways associated with rises in [Ca2+]i (Lin et al. 1991) . However, inhibition by FK-506 and CsA of interleukin-2 synthesis is not associated with a reduction in [Ca2+] i (Metcalfe 1984; Ryffel 1989; Bierer et al. 1990 ). The intracellular binding proteins for , respectively, do not share amino acid sequence homology (Siekierka et al. 1989; Harding et al. 1989 ), but both immunosuppressant-immunophilin-complexes inhibit the CaZ+-/calmodulin-dependent phophatase, calcineurin (Liu et al. 1991) .
At therapeutic concentrations CsA only marginally inhibits human neutrophil activation (Janco and English 1983; Kharazmi et al. 1985; Wenzel-Seifert et al. 1991) . Interestingly, FK-506 has recently been reported to be a very potent and effective inhibitor of A 23187-induced exocytosis in human neutrophils (Forrest et al. 1991) . Additionally, FK-506 partially inhibits interleukin-la release from human macrophages (Keicho et al. 1991 ) and potently inhibits mediator release from basophils and mast cells (De Paulis et al. 1991a, b; Hultsch et al. 1991) . All these findings prompted us to study in detail the effects of FK-506 on human neutrophil activation. We show here that FK-506 partially inhibits O~-production and exocytosis at supratherapeutic concentrations.
Materials and methods

Materials. FK-506 was kindly provided by Fujisawa Pharmaceutical
Co., Ltd. (Osaka, Japan). Stock solutions of FK-506 (1 mM) were prepared in dimethyl sulfoxide and were stored in polypropylene tubes at -20°C under light protection for up to two months. Dilutions of FK-506 were made immediately prior to experiments. The final concentration of dimethyl sulfoxide in all experiments was adjusted to 0.1% (v/v). 12-(9-Anthroyloxy)-stearate (12-AS) was obtained from Molecular Probes (Junction City, Ore., USA); 1,6-diphenylhexa-l,3,5-triene (DPH) was from EGA Chemic (Steinheim, FRG). Stock solutions of DPH (2 mM) were prepared in tetrahydrofurane and were kept at 25 °C. Stock solutions of 12-AS (1 raM) were prepared in 80% ethanol (v/v) and were kept at -20°C. Sources of other materials have been described elsewhere (Seifert et al. 1989a (Seifert et al. , b, 1992 Wenzel-Seifert and Seifert 1990; Wenzel-Seifert et al. 1991) .
Isolation of human neutrophils. Neutrophils were obtained from 12 caucasian healthy volunteers (six males and six females) approximately 2 h after a continental breakfast. Volunteers had taken no drugs for at least three weeks. The age of volunteers ranged from 28-40 years; six of them were smokers. Isolation of neutrophils was performed as described (Seifert et al. 1989a) . Cell preparations consisted of >95% viable neutrophils as revealed by trypan blue dye exclusion and Pappenheim-stained smears.
Assay for Oj production. 0 2 production was monitored at 550 nm by continuous measurement of ferricytochrome C reduction inhibitable by superoxide dismutase, using an Uvikon 810 dual beam spectrophotometer (Kontron, Eching, FRG) (Seifert et al. 1989a) . Reaction mixtures (0.5 ml) contained 100 ~tM ferricytochrome C and a buffer consisting of (mM) 138NaC1, 6KCI, 1MgC12, 1CaC12, 5.5 glucose and 20 Hepes/NaOH, pH 7.4. Neutrophils (1.0-2.0x 106 cells) or dibutyryl cAMP-differentiated HL-60 cells (2.5 × 10 6 cells) were suspended in the solution described above and were incubated for 5 min at 37 °C in the presence of FK-506 or solvent. 0 2 production was initiated by the addition of stimuli.
Assay for fl-glucuronidase and lysozyme release. Exocytosis was assessed as described (Seifert et al. 1989b; Wenzel-Seifert and Seifert 1990; Wenzel-Seifert et al. 1991) . In one set of experiments, neutrophils (4.0-5.0x106 cells) were incubated for 5min at 37°C in the buffer (0.5 ml) described above supplemented with cytochaiasin B (5 gg/ml) in the presence of FK-506 or solvent. Thereafter, stimuli were added to cells. In another set of experiments, neutrophils (4.0-5.0x106 ceils) were incubated for 25min at 20°C in the buffer (0.5ml) described above not supplemented with cytochalasin B, in the presence of FK-506 or solvent. Thereafter, cells were incubated for additional 5 min at 37 °C in the presence of FK-506 or solvent plus cytochalasin B (5 gg/ml). Subsequently, stimuli were added to cells. Reactions were terminated after i0 min by rapid cooling to 4 °C. Reaction mixtures were centrifuged for 10min at 1000xg. The determinations of the activities of flglucuronidase, lysozyme and lactate dehydrogenase of the supernatant fluids of reaction mixtures and of cell lysates were performed as described (Seifert et al. 1989b; Wenzel-Seifert and Seifert 1990; WenzelSeifert et al. 1991) . Basal fl-glucuronidase, lysozyme and lactate dehydrogenase release amounted to less than 5°70 of cellular content (data not shown). Ca2+] i. [Caa+] i was determined using the fluorescent dye, Fura-2, as described (Wenzel-Seifert and Seifert 1990) . Neutrophils were suspended at 5xl06cells/ml in a buffer consisting of (mM) 138 NaC1, 6 KC1, 1 MgSO4, 1.1 CaCI2, 0.I EGTA, 1 NaaHPO4, 5 NaHCO3, 5.5 glucose, 20 Hepes/NaOH, pH 7.4, supplemented with bovine serum albumin (0.1070, w/v). Cells were incubated for 1 h at 37 °C in the presence of Fura-2 acetoxymethylester (4 IxM). Subsequently, cells were diluted with the above buffer to a final concentration of 0.5 × 10 6 cells/ml and were centrifuged for 10 min at 250x g at 20 °C. Cells were suspended at 2.5 x 106 cells/ml in the above buffer and were kept at 20°C until measurement of [CaZ+] i. Fluorescence of neutrophils (2.5 x 106 cells in 2 ml) was determined at 37 °C under constant stirring at 103 rpm using a Ratio II spectrofluorometer (Aminco, Silver Spring, Md., USA). Cells were incubated for 5 rain in the presence of FK-506 or solvent prior to the addition of stimuli. The excitation and emission wavelengths were 340 and 500 nm, respectively.
Measurement of[
Cell culture and membrane preparation. HL-60 ceils were cultured in suspension culture at 37 °C and were differentiated towards neutrophillike cells upon incubation with dibutyryl cAMP (0.2 raM) for 48 h (Seifert et al. 1989a; Wenzel-Seifert and Seifert 1990) . In some experiments, FK-506 or solvent were added to cultures 24 h prior to experiments. HL-60 membranes were prepared as described (Seifert and Schultz 1987) .
Steady-state and differential polarized phase fluorometry. DPH and
12-AS were added from stock solutions to fluorometry buffer consisting of (mM) 100 mannitol, 10 Hepes/Tris, pH 7.4, and were stirred at 25 °C for 1 h and 5 min, respectively, to remove solvent. HL-60 membranes were suspended in these solutions to give final probe concentrations of 1 ~xM (DPH) and 2 ~tM (12-AS); these mixtures were incubated in the dark for 30 min at 37 °C. Membranes were centrifuged for 20 min at 48000×g at 4°C and were resuspended in fluorometry buffer at 0.15 mg of protein/ml. Membranes were incubated for 10 min at 25 °C in the presence of FK-506 or solvent. Fluorescence measurements were performed at 25 °C in a SLM 4800 spectrofluorometer (SLM Instruments, Urbana, Ill. USA) equipped with a thermostated cuvette holder. Steady state-anisotropy was measured on the T formate with 360 nm (DPH) and 365 nm (12-AS) as excitation wavelengths. Emission light was filtered through KV-418 filters (Schott, Mainz, FRG). Fluorescence lifetimes were measured at 18 MHz by the phase modulation technique relative to a glycogen scatter solution (Spencer and Weber 1969) . Differential tangent was measured by differential polarized phase fluorometry at 18 MHz (Lakowicz et al. 1979 ). Rotational correlation time and limiting anisotropy were calculated from steady-state anisotropy, phase lifetime, differential tangent and r 0, i.e. the anisotropy in the absence of motion (Lakowicz et aI. 1979) . R 0 values of 0.390 (DPH) (Lakowicz et al. 1979 ) and 0.285 (12-AS) (Schachter and Shinitzky 1977) were used for calculations.
fMet-Leu-[3H]Phe binding assay, fMet-Leu-[3H]
Phe binding was performed as described (Wenzel-Seifert et al. 1991) . Reaction mixtures (100 Ixl) contained 40 ~g of membrane protein from dibutyryl cAMPdifferentiated HL-60 cells, bovine serum albumin (0.2%, w/v), 50 mM Tris/HC1, pH 7.3, 1 mM EDTA and 5 mM MgC12 in the presence of FK-506 or solvent. Incubations were conducted for 30 min at 25 °C and were initiated by the addition of 3 nM fMet-Leu-[3H]Phe. Reactions were terminated by rapid filtration technique. Radioactivity on dried filters was determined in a liquid scintillation counter. Unspecific binding was determined in the presence of 10 ~xM fMet-Leu-Phe and amounted to less than 10070 of total binding.
Measurement of GTPase activity. GTPase activity was measured as described (Seifert et al. 1992) . Assay mixtures (:tO0 gl) contained membranes from HL-60 cells ( .7. of creatine kinase, 1 mM dithiothreitol and 0.2% (w/v) bovine serum albumin in 50 mM triethanolamine/HC1, pH 7.4. Reaction mixtures were preincubated for 10min at 25°C with FK-506 or solvent. Thereafter, ._g fMet-Leu-Phe or H~O were added. After additional 10 min at 25 °C, reactions were initiated by the addition of [y-32P]GTP and were con-~ ducted for 15 min. Low-affinity GTPase activity was determined in the presence of GTP (50 p~M) and amounted to < 5 % of total GTPase activity.
Miscellaneous. Protein was determined according to Lowry et al. (1951) . The effects of FK-506 were statistically assessed using the Wilcoxon test.
Results
First, the effects of FK-506 on cell integrity were studied. FK-506 up to 1 gM did not cause damage of neutrophits and HL-60 cells as revealed by lactate dehydrogenase release and trypan blue dye exclusion (data not shown).
The effect of FK-506 at various concentrations on 0 2 production induced by fMet-Leu-Phe (50nM) is shown in Fig. 1 . FK-506 above 100 nM inhibited the absolute amount and maximum rate of O~-production by up to 35%. At lower concentrations, FK-506 was ineffective.
The effects of FK-506 (1 gM) on 0 2 production and on rises in [Ca2+l i induced by various stimuli were studied. fMet-Leu-Phe activated 0 2 production with an EC50 of 45 nM and a maximum at 300 nM (Fig. 2) . FK-506 reduced O~-production by about 30% at all fMet-Leu-Phe concentrations employed, and it did not substantially increase the ECs0. fMet-Leu-Phe increased [Ca2+li with an EC50 of 0.4nM and a maximum at 30 nM (see Fig. 2 ); FK-506 was without effect on rises in r----I i The effects of FK-506 on exocytosis are shown in Table1. FK-506 (l~tM) inhibited A23187-induced flglucuronidase and lysozyme release by 30-40%, regardless of whether cells were incubated with the drug for 25 min at 20 °C plus 5 min at 37 °C or only for 5 min at 37°C. FK-506 did not inhibit fMet-Leu-Phe-and PAFF-induced exocytosis. FK-506 per se did not activate exocytosis (data not shown).
Modulation by FK-506 of Of production in dibutyryl cAMP-differentiated HL-60 cells is shown in Table 2 . After preincubation for 5 rain at 37 °C FK-506 inhibited fMet-Leu-Phe-induced O~-production by about 20%. By comparison, fMet-Leu-Phe-induced O2 production was not altered in cells preincubated with FK-506 for 24 h at 37 °C.
The effect of FK-506 on binding of fMetLeu-[3H]Phe (3 nM) to formyl peptide receptors in membranes from dibutyryl cAMP-differentiated HL-60 cells was investigated. Agonist-binding in control membranes was 568+27 fmol/mg protein. (1 gM) did not alter agonist-binding to formyl peptide receptors (569_+ 24 fmol/mg protein).
Modulation by FK-506 of high-affinity GTPase activity in membranes from dibutyryl cAMP-differentiated HL-60 cells was studied. Basal GTP hydrolysis was 17.1 ___ 1.5 pmol Pi/mg protein/rain, fMet-Leu-Phe (0.3 gM) stimulated GTP hydrolysis by 80%. FK-506 (1 ~tM) showed no effect on basal and fMetLeu-Phe-stimulated GTP hydrolysis (data not shown).
Finally, the effect of FK-506 on physical state of HL-60 membranes was studied. Steady-state anisotropy in control membranes was 0.2109_+0.0033 with DPH as probe. Phase lifetime of DPH was 9.47 +0.07 ns. Limiting anisotropy was 0.180_+0.002 and rotational correlation time was 1.62+0.11 ns. FK-506 (1 ~tM) had no effect on these parameters (data not shown). Steady-state anisotropy and phase lifetime of 12-AS in control membranes were 0.0849_+0.0015 and ll.12_+0.10ns, respectively; FK-506 (1 gM) showed no effect on these parameters. FK-506 did not change limiting anisotropy and rotational correlation time of 12-AS in HL-60 membranes (data not shown).
Discussion
We found that FK-506 partially inhibited fMet-Leu-Pheand PAF-induced 02 production and A23187-induced exocytosis in human neutrophils at a supratherapeutic concentration (1 gM) (see Figs. 2 and 3 and Table i ) (Starzl et al. 1989 ). Additionally, FK-506 (1 gM) slightly inhibited fMet-Leu-Phe-induced O; production in differentiated HL-60 cells (see Table2) . These findings prompted us to study the effects of FK-506 at therapeutic concentrations on fMet-Leu-Phe-induced 02 production in human neutrophils as fMet-Leu-Phe is assumed to play a key role in neutrophil activation in bacterial infec-tions (see Fig. 1 ) (Rossi 1986; Sandborg and Smolen 1988; Seifert and Schultz 1991) . However, at therapeutic concentrations (0.1-1 nM) (Starzl et al. 1989) , FK-506 did not inhibit O~-production induced by fMet-Leu-Phe (see Fig. 1 ). Additionally, FK-506 was without effect on O~-formation induced by leukotriene B 4 and CSa, two other physiologically relevant chemoattractants (Rossi 1986; Sandborg and Smolen 1988; Seifert and Schultz 1991) . Furthermore, FK-506 did not at all affect exocytosis induced by fMet-Leu-Phe and PAF (see Table 1 ). These data suggest that the only partial inhibition of neutrophil activation by FK-506 at supratherapeutic concentrations is without clinical relevance and that FK-506 at therapeutic concentrations is unlikely to impair the non-specific defense system substantially.
The effects of FK-506 on neutrophil activation showed some similarities with the corresponding effects of CsA. The effectiveness of CsA and FK-506 (1 gM each) to inhibit fMet-Leu-Phe-induced O~-production is similar (see Figs. 1 and 2) (Wenzel- Seifert et al. 1991) . Like CsA, FK-506 did not inhibit fMet-Leu-Phe-and PAF-induced exocytosis and rises in [Ca2+]i (see Figs. 2 and 3 and Table 1 ) (Wenzel-Seifert et al. 1991) . Similar to CsA, FK-506 did not interfere with agonist-binding to formyl peptide receptors (Wenzel-Seifert et al. 1991) . However, unlike CsA, FK-506 partially inhibited PAF-induced O~-production (see Fig. 3 ) (Wenzel-Seifert et al. 1991) . These data suggest that FK-506 and CsA inhibit neutrophil activation through related but not identical mechanisms.
FKBP is ubiquitously distributed in eukaryotic cells (Siekierka et al. 1989) . In human lymphocytes, the potency of FK-506 in functional assays (ICs0 approximately 0.1 nM) is in accordance with the affinity of FK-506 to FKBP (KD) of 0.4-0.8 nM) (Sigal and Dumont 1992; Siekierka et al. 1989) . These data suggest that the FK-506-FKBP complex mediates the immunosuppressive effects of the drug in these cells. In addition, FK-506 inhibits activation of mast cells and basophils with ICs0 values of 1-5 nM (De Paulis et al. 1991a, b; Hultsch et al. 1991) . By comparison, FK-506 at these concentrations was without effect on fMet-Leu-Phe-induced O~-production, and FK-506 (1 gM) showed no or only relatively small inhibitory effects on various neutrophil activation parameters (see Figs. 1 -3 and Tables 1 and 2 ). These data suggest that the inhibitory effects of FK-506 on neutrophil activation are not mediated by the FK-506-FKBP complex. It cannot, however, be excluded that FK-506 penetrates the neutrophil plasma membrane only poorly, i.e. the drug has to be present at very high extracellular concentrations to reach sufficient concentrations in the cytosol for interaction with FKBP.
Several other possibilities have to be discussed to explain the inhibitory effects of FK-506 on human neutrophil activation. First, the failure of FK-506 to inhibit agonist-binding to formyl peptide receptors suggests that it does not act as formyl peptide receptor antagonist. Second, the lack of effect of FK-506 on high-affinity GTPase in HL-60 membranes indicates that the drug does not interfere with G-proteins. Third, FK-506 did not inhibit PMA-induced O~-production suggesting that it does not act as inhibitor of protein kinase C. Fourth, the lack of effect of FK-506 on 02 production induced by various stimuli implies that it does not interfere with a component of NADPH oxidase, the 02-generating enzyme system (Rossi 1986; Seifert and Schultz 1991) . Similarly, the failure of FK-506 to inhibit exocytosis by various stimuli implies that it does not interfere with secretory mechanisms in an unspecific manner (see Table 1 ). Additionally, the lack of effect of FK-506 on fMet-Leu-Phe-and PAFinduced rises in [Ca2+]i indicates that the drug does not interfere with Ca 2+ mobilization and/or Ca 2+ influx from the extracellular space (see Figs. 2 and 3) . Furthermore, we did not observe toxic effects of FK-506 on human neutrophils. Finally, the inhibitory effects of FK-506 were evident after short-term preincubation of cells but not after long-term treatment (see Figs. 1 -3 and Tables 1 and 2 ). Thus, FK-506 apparently does not act via inhibition of gene transcription or protein synthesis. Interestingly, inhibitory effects of FK-506 on basophil and mast cell activation are also evident after short-term preincubation (De Paulis et al. 1991 a,b; Hultsch et al. 1991) .
FK-506 is a very lipophilic drug (Kino et al. 1987 ). This fact and the supratherapeutic concentrations of FK-506 required to partially inhibit neutrophil activation (see Fig. 1 ) (Starzl et al. 1989 ) raise the question of whether the drug acts via alteration of physical membrane state. A widely employed technique for the study of physical membrane state is steady-state polarization and differential polarized phase fluorometry with DPH and 12-AS as probes. Absolute steady-state anisotropy of DPH in dibutyryl cAMP-differentiated HL-60 membranes was similar to the one in membranes from dimethyl sulfoxide-differentiated HL-60 cells, human neutrophils, lymphocytes and erythrocytes (Shinitzky and Inbar 1974; Ip and Cooper 1980; Giraud et al. 1991; Yuli et al. 1982) . Limiting anisotropy reflects lipid packing order in the membrane restricting the probes' rotational motion, i.e. it is a static measure; rotational correlation time reflects mobility of the probe in the lipid environment, i.e. it is a dynamic measure (Lakowicz et al. 1979) . The lack of effect of FK-506 on limiting anisotropy and rotational correlation time clearly argues against alterations in physical membrane state accounting for its partial inhibitory effects on neutrophil activation. Taken together, the mechanism of action of FK-506 in human neutrophils is still unknown.
There are some similarities and dissimilarities between the results obtained by us und by Forrest et al. (1991) . In agreement with our data are their findings that FK-506 and CsA do not inhibit fMet-Leu-Phe-induced exocytosis (see Table 1 ) (Wenzel-Seifert et al. 1991) . However, Forrest et al. (1991) reported that FK-506, after preincubation for 25 min at room temperature, inhibited exocytosis induced by A23187 at a maximally effective concentration (1 gM) in human neutrophils with an ICs0 of about 1 nM and a maximum at 10 nM. In our hands, A23187 was maximally effective at 5gM, whereas A23187 at i gM induced the release of only about 5% of the cellular content of fl-glucuronidase release, i.e. this stimulation was too small for reliable quantitative assessment of the inhibitory effect of FK-506 (data not shown).
Differences in the maximally effective concentrations of A23187 for stimulation of exocytosis among various groups have been reported before (Kang et al. 1985; Becker et al. 1985; Naccache et al. 1985) . In contrast to Forrest et al. (1991) , we found that FK-506 as high as 1 ~tM showed only relatively small inhibitory effects on A23 187-induced exocytosis, regardless of whether cells were preincubated with the drug for 25 min at 20 °C plus 5 rain at 37 °C or only for 5 min at 37 °C (see Table 1 ). Basically, the methods applied by us and by Forrest et al. (1991) (see Materials and methods) were similar. It is possible that differences in responsiveness to FK-506 of neutrophils in both studies existed. Interestingly, Kahan et al. (1991) reported on substantial variation in responsiveness to FK-506 among lymphocytes from different donors. In addition, it is known that regulation of 02 production may depend on several conditions such as sex, age, active and passive smoking, feeding state and method of cell isolation (Seifert and Schultz 1991; Lipschitz et al. 1991; Anderson et al. 1991; Uhlinger et al. 1991) . With regard to the donors studied by us, however, FK-506 showed very consistent effects (see Figs. 1-3 and Table  1 ). Specifically, we did not observe that neutrophils of some donors were highly sensitive to inhibition by FK-506, whereas cells from other donors were insensitive. Unfortunately, Forrest et al. (1991) did not provide sufficient information on the above-mentioned factors in their volunteers. Regardless of the reason for the differences between our results and those of Forrest et al. (1991) should it be kept in mind that A23 187, unlike fMetLeu-Phe, C5a, PAF and leukotriene B4, is not a physiologically relevant stimulus (Rossi 1986; Sandborg and Smolen 1988; Seifert and Schultz 1991) .
In conclusion, we have shown that FK-506 at therapeutic concentrations does not inhibit human neutrophil activation. At supratherapeutic concentrations FK-506 partially inhibits neutrophil activation through a mechanism which is rapid in onset and does not involve inhibition of agonist binding to formyl peptide receptors, interference with G-proteins or protein kinase C, reduction of rises in [Ca2+]i or changes in physical membrane state.
